K. Rene Ward
Associate Director, Public Relations and Internal Communications
3902 Gene Field Road
St. Joseph, Missouri 64506
You can’t afford the cost of a trich outbreak in your herd. It’s time to stop ignoring the problem and prevent the spread. Here’s how.
Record-breaking beef prices only make the problem worse. Besides being a herd health and biosecurity nightmare, trichomoniasis is costing producers missed dollars across the country. In states like Arkansas, emergency bull testing requirements were passed this summer due to outbreaks. In Colorado, the Board of Animal Health is reminding producers of the importance of testing because of seven trich-positive areas in that state. The list of affected states could go on. Trich is becoming more prevalent and costly every day, and you simply can’t ignore it anymore.
Cows that interact with trichomoniasis-infected bulls — whether yours or those from a neighboring herd — run a strong risk of becoming infected themselves. Unlike cows, infected bulls show no symptoms of the disease and are hard to identify without testing.
When cows breed with an infected bull, the organism that causes trichomoniasis, Tritrichomonas foetus, attaches itself to the vaginal wall. This environment is perfect for T. foetus, with a pH between 6.0 and 7.5 and thick walls for easy attachment. Once they’re attached, the organisms will colonize and spread throughout the uterus and oviducts, causing the uterus to have an inflammatory response.
It is likely that the cow will still conceive after breeding with the infected bull. The infection she contracts, however, will ultimately lead to embryonic death or abortion, due to the inflammatory response of the uterus.
In some cases, the inflammatory response will occur within the first 18 days after breeding. When this happens, cows usually return to heat in their next 21-day cycle. Those cows returning to heat can have the ability to infect any bull that breeds her until she clears the uterus of infection, which can take up to 80 days. In most situations, embryonic death will occur between 50 and 60 days post breeding. When this happens, there may be an abortion of a small fetus or a pyometra formation (a pus-filled uterus). In very rare cases, it may take anywhere from seven to eight months for the infection to result in an inflammatory response and, ultimately, abortion.
When you pregnancy-check your cows and find that one is open, you will have a decision to make. Do you breed her again or cull her? It takes anywhere from two to four months for the trichomoniasis infection to clear her system, which may affect any rebreeding and could pose a risk to healthy herd bulls. Beyond that, the cow will have a lighter calf due to late breeding, and will most likely calve later than the rest of the herd for her entire lifetime.
One trichomoniasis-infected animal can spread disease throughout your entire herd, with the possibility of reducing your calf crop by as much as 50 percent. In a 100-head herd, you could lose $20,000 or more. Reasons for economic losses are threefold:
While the bull is the primary disease carrier, preventive measures can help reduce trichomoniasis prevalence among both bulls and cows. Early prevention may also be the best option for those cattle that have the opportunity to mingle with neighboring herds that are out of your control.
While there is no treatment for trichomoniasis, there is currently one vaccine available that has been proven to aid in the prevention of disease caused by Tritrichomonas foetus. TrichGuard® and TrichGuard® V5L, available from Boehringer Ingelheim Vetmedica, Inc., are the first vaccines to protect against T. foetus devastation.
In a university study, TrichGuard improved calving percentages by more than 90 percent compared to unvaccinated cows whose calving percentage was only 32 percent.1 While it won’t prevent trichomoniasis in your cowherd, vaccinating with TrichGuard vaccine will help lessen its impact and reduce calving losses resulting from trichomoniasis.
TrichGuard is a registered trademark of Boehringer Ingelheim Vetmedica, Inc. ©2011 Boehringer Ingelheim Vetmedica, Inc.
1Kvasnicka WG, DVM, et al. Clinical evaluation of the efficacy of inoculating cattle with a vaccine containing Tritrichomonas foetus. Am Journal of Vet Res 1992;53(11).
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.